drugset

drugset / Trial / NCT00319033

Open-label Study With Bosentan in Interstitial Lung Disease

NCT00319033 ↗

Phase 2/3 Completed 132 enrolled Actelion

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will asses the long term safety and efficacy of oral bosentan to patients suffering from Interstitial Lung Disease.

Timeline

Start: 2004-07
Primary completion: 2006-02
Completion: 2006-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bosentan	Other / unclassified	—	Oral

Indications